Stockreport

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF investigational candidate, batoclimab, which is being developed for Graves' Disease (GD). IMVT's Batoclimab Shows Superior Efficacy in GD Patients The enrolled patie [Read more]